Net sales increased to 757 tkr in 2025, but losses remained high at -17,705 tkr. Several new commercial agreements and a 13.3 MSEK rights issue strengthened liquidity, supporting ongoing commercialization and R&D efforts.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.